FAQ

AR C124910XX

Known as: AR-C124910XX 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
012320102016

Related topics

Related topics

2 relations

Broader (1)

Adenosine
analogs & derivatives

Related mentions per year

Related mentions per year

1937-2018
19401960198020002020
AR C124910XX
Adenosine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.
OBJECTIVE The population pharmacokinetics of ticagrelor and its active metabolite AR-C124910XX were characterized following… (More)
Is this relevant?
2016
2016
Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.
OBJECTIVE The objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
PURPOSE A combination of clopidogrel and aspirin is the standard treatment for patients with acute coronary syndrome and those… (More)
Is this relevant?
2015
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective…
OBJECTIVES The goal of this study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of escalating… (More)
Is this relevant?
2012
2012
Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.
WHAT IS KNOWN AND OBJECTIVE Ticagrelor is the first reversibly binding oral P2Y(12) receptor antagonist and has been approved in… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2012
2012
Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals
The aim of this study was to assess age and gender effects on ticagrelor pharmacokinetics and pharmacodynamics (PK/PD). Forty… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2012
2012
Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers
Interactions between ticagrelor and atorvastatin or simvastatin were investigated in two-way crossover studies. Both studies were… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS.
Ticagrelor is the first direct acting reversibly binding oral platelet P2Y(12) receptor antagonist. The parent molecule and the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.
Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d… (More)
Is this relevant?
2010
2010
Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry.
Rapid and sensitive analytical methods using liquid chromatography with tandem mass spectrometry (LC/MS/MS) were developed for… (More)
Is this relevant?